The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Zika virus set to spread across Americas, spurring vaccine hunt

Mon, 25th Jan 2016 17:14

* Mosquito-borne virus linked to birth defects in Brazil

* Brazil's Butantan Institute aims to develop vaccine

* GSK and Sanofi reviewing vaccine possibilities

* More research needed into potential sexual transmission (Adds comment from GlaxoSmithKline and Sanofi, graphic link)

By Tom Miles and Ben Hirschler

GENEVA/LONDON, Jan 25 (Reuters) - The mosquito-borne Zikavirus, which has been linked to brain damage in thousands ofbabies in Brazil, is likely to spread to all countries in theAmericas except for Canada and Chile, the World HealthOrganization said on Monday.

Zika transmission has not yet been reported in thecontinental United States, although a woman who fell ill withthe virus in Brazil later gave birth to a brain-damaged baby inHawaii.

Brazil's Health Ministry said in November that Zika waslinked to a foetal deformation known as microcephaly, in whichinfants are born with smaller-than-usual brains.

Brazil has reported 3,893 suspected cases of microcephaly,the WHO said last Friday, over 30 times more than in any yearsince 2010 and equivalent to 1-2 percent of all newborns in thestate of Pernambuco, one of the worst-hit areas.

The Zika outbreak comes hard on the heels of the Ebolaepidemic in West Africa, demonstrating once again howlittle-understood diseases can rapidly emerge as global threats.

"We've got no drugs and we've got no vaccines. It's a caseof deja vu because that's exactly what we were saying withEbola," said Trudie Lang, a professor of global health at theUniversity of Oxford. "It's really important to develop avaccine as quickly as possible."

Large drugmakers' investment in tropical disease vaccineswith uncertain commercial prospects has so far been patchy,prompting health experts to call for a new system of incentivesfollowing the Ebola experience.

"We need to have some kind of a plan that makes (companies)feel there is a sustainable solution and not just a one-shotdeal over and over again," Francis Collins, director of the U.S.National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute is currently leadingthe research charge on Zika and said last week it planned todevelop a vaccine "in record time", although its director warnedthis was still likely to take three to five years.

British drugmaker GlaxoSmithKline said on Monday itwas studying the feasibility of using its vaccine technology onZika, while France's Sanofi said it was reviewingpossibilities.

RIO CONCERNS

The virus was first found in a monkey in the Zika forestnear Lake Victoria, Uganda, in 1947, and has historicallyoccurred in parts of Africa, Southeast Asia and the PacificIslands. But there is little scientific data on it and it isunclear why it might be causing microcephaly in Brazil.

Laura Rodrigues of the London School of Hygiene and TropicalMedicine said it was possible the disease could be evolving.

If the epidemic was still going on in August, when Brazil isdue to host the Olympic Games in Rio de Janeiro, then pregnantwomen should either stay away or be obsessive about covering upagainst mosquito bites, she said.

The WHO advised pregnant women planning to travel to areaswhere Zika is circulating to consult a healthcare providerbefore travelling and on return.

The clinical symptoms of Zika are usually mild and oftensimilar to dengue, a fever which is transmitted by the sameAedes aegypti mosquito, leading to fears that Zika will spreadinto all parts of the world where dengue is commonplace.

More than one-third of the world's population lives in areasat risk of dengue infection, in a band stretching throughAfrica, India, Southeast Asia and Latin America.

Zika's rapid spread, to 21 countries and territories in theAmericas since May 2015, is due to the prevalence of Aedesaegypti and a lack of immunity among the population, the WHOsaid in a statement.

RISK TO GIRLS

Like rubella, which also causes mild symptoms but can leadto birth defects, health experts believe a vaccine is needed toprotect girls before they reach child-bearing age.

Evidence about other transmission routes, apart frommosquito bites, is limited.

"Zika has been isolated in human semen, and one case ofpossible person-to-person sexual transmission has beendescribed. However, more evidence is needed to confirm whethersexual contact is a means of Zika transmission," the WHO said.

While a causal link between Zika and microcephaly has notyet been definitively proven, WHO Director-General Margaret Chansaid the circumstantial evidence was "suggestive and extremelyworrisome".

In addition to finding a vaccine and potential drugs tofight Zika, some scientists are also planning to take the fightto the mosquitoes that carry the disease.

Oxitec, the UK subsidiary of U.S. synthetic biology companyIntrexon, hopes to deploy a self-limiting geneticallymodified strain of insects to compete with normal Aedes aegypti.

Oxitec says its proprietary OX513A mosquito succeeded inreducing wild larvae of the Aedes mosquito by 82 percent in anarea of Brazil where 25 million of the transgenic insects werereleased between April and November. Authorities reported a bigdrop in dengue cases in the area.

(Editing by Mark Trevelyan)

More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.